Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards
12:27pm, Thursday, 31'st Jul 2025
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib alt
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Wednesday, 30'th Jul 2025
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
2 Highly Ranked Stocks to Consider After Q2 Earnings: CLS, EXEL
10:36pm, Tuesday, 29'th Jul 2025
Investors looking for a momentum stock that could be in store for higher highs may want to consider Celestica (CLS), while those looking for a buy-the-dip target have an intriguing option with Exelixi
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy
01:00pm, Tuesday, 29'th Jul 2025
Exelixis (EXEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans
12:32pm, Tuesday, 29'th Jul 2025
Exelixis Inc. EXEL on Monday reported its first quarter of 2025 adjusted earnings of 75 cents per share, compared to 85 cents a year ago, beating the consensus of 56 cents.
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
10:42am, Tuesday, 29'th Jul 2025
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
10:51pm, Monday, 28'th Jul 2025
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical A
Exelixis (EXEL) Beats Q2 Earnings Estimates
06:21pm, Monday, 28'th Jul 2025
Exelixis (EXEL) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.84 per share a year ago.
Exelixis Q2 Revenue Falls 11 Percent
05:34pm, Monday, 28'th Jul 2025
Exelixis Q2 Revenue Falls 11 Percent
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Monday, 28'th Jul 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objective
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:51am, Monday, 28'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) for the treatm
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
11:55am, Wednesday, 23'rd Jul 2025
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:45am, Wednesday, 23'rd Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
10:16am, Wednesday, 23'rd Jul 2025
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some
